Valuation: Exagen Inc.

Market Cap 187M 166M 154M 140M 265M 17.75B 269M 1.85B 726M 9.26B 702M 687M 29.53B P/E 2026 *
-11.7x
P/E 2027 * -15x
Enterprise Value 187M 166M 154M 140M 265M 17.75B 269M 1.85B 726M 9.26B 702M 687M 29.53B EV / Sales 2026 *
2.53x
EV / Sales 2027 * 2.29x
Free-Float
61.46%
Yield 2026 *
-
Yield 2027 * -
1 day-9.81%
1 week-8.31%
Current month-5.04%
1 month-1.91%
3 months+75.85%
6 months+150.65%
Current year+26.97%
1 week 7.3
Extreme 7.3
9.22
1 month 7.3
Extreme 7.3
9.22
Current year 2.59
Extreme 2.59
9.22
1 year 2.59
Extreme 2.59
12.23
3 years 1.3
Extreme 1.3003
12.23
5 years 1.3
Extreme 1.3003
14.85
10 years 1.3
Extreme 1.3003
29.86
Manager TitleAgeSince
Chief Executive Officer 41 2022-10-16
Director of Finance/CFO 57 2024-08-31
Chief Tech/Sci/R&D Officer - 2025-06-22
Director TitleAgeSince
Chairman 73 2023-01-18
Director/Board Member 63 2019-07-29
Director/Board Member 56 2021-06-16
Date Insider Type Main position Quantity % Market Cap. Importance
9/1/26 Sell

Chief Financial Officer

-22,185 0.0916%
3/12/26 Free

Chief Financial Officer

126,511 0.5582%
3/12/26 Free

Chief Executive Officer

250,000 1.1031%
Change 5-day change 1-year change 3-year change Capi.($)
-9.81%-8.31%-33.10%+359.52% 187M
-0.24%+7.20%+11.92%+28.26% 118B
-2.06%+1.72%+7.67%+88.07% 99.34B
-2.80%-1.81%+116.54%+825.74% 56.71B
+2.78%+6.42%-5.38%+78.37% 28.56B
-1.74%+1.74%+24.00%+90.61% 25.94B
-2.19%+1.86%+11.19%+56.66% 25.79B
-2.86%+1.32%+33.62%+373.09% 21.52B
-0.27%-2.46%-20.43%-2.63% 20.76B
-0.65%-6.95%+4.36%+84.85% 18.25B
Average -1.98%-0.11%+15.04%+198.25% 41.52B
Weighted average by Cap. -1.19%+2.39%+23.87%+179.58%

Financials

2026 *2027 *
Net sales 73.91M 65.7M 60.9M 55.41M 105M 7.02B 106M 732M 287M 3.66B 277M 271M 11.67B 81.51M 72.46M 67.16M 61.1M 115M 7.74B 117M 807M 317M 4.04B 306M 299M 12.87B
Net income -15.93M -14.16M -13.13M -11.94M -22.54M -1.51B -22.9M -158M -61.87M -789M -59.8M -58.52M -2.52B -13.38M -11.89M -11.02M -10.03M -18.93M -1.27B -19.23M -133M -51.95M -663M -50.22M -49.15M -2.11B
Net Debt - -
Projected Income Statement - Annual - Exagen Inc.
Logo Exagen Inc.
Exagen Inc. is a provider of autoimmune diagnostics focused on transforming care for patients with chronic and debilitating autoimmune conditions. The Company is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related disease including, among others, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.
Employees
218
Date Price Change Volume
26-10-16 US$7.720 -9.81% 966,186
26-10-15 US$8.560 +1.66% 393,903
26-10-14 US$8.420 -0.71% 613,480
26-10-13 US$8.480 +2.79% 469,991
26-10-12 US$8.250 -2.02% 201,396
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Exagen Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
7.720USD
Average target price
10.29USD
Spread / Average Target
+33.23%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Exagen Inc.